Samsung Bioepis releases 1st qtr 2026 US biosimilar market report

South Korea’s Samsung Bioepis today released its first quarter 2026 biosimilar market report, marking the twelfth edition of the Quarterly Biosimilar Market Report in the United States (US) today.

The report provides an overview of the market status of all biosimilars available in the US, including approval and launch status, pricing (both average sales price [ASP] and wholesale acquisition cost [WAC]), and market uptake per molecule. The Deep Dive section in this edition provides an overview of the evolving US pharmacy benefit manager (PBM) rebate contract model and how its frameworks may potentially impact the biosimilar market.

“As the US healthcare market enters 2026, stakeholders’ approaches to prescription drug pricing and management continue to evolve. Alongside established PBM contracting structures, new models emphasizing alternative pricing reimbursement, transparency, and a shift towards more fiduciary responsibility have emerged in response to changing market conditions,” said Thomas Newcomer, vice president, head of US commercial operations, at Samsung Bioepis, adding: “In this quarter’s report, we provide an overview of these developments and consider how evolving PBM rebate frameworks may influence utilization patterns, including potential implications for biosimilars.”